Showing results (61-70 of 77) with videos related to
Sort By:
Pageof 8
Endocrine Research|January 1, 1992
B-endorphin response to a low dosage of human corticotropin releasing hormone during metyrapone administration in depressionJ Lisansky, R Hauger, R Strassman, et al.The Journal of Clinical Endocrinology and Metabolism|October 16, 1999
Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal menA S Dobs, A W Meikle, S Arver, et al.The Journal of Urology|May 1, 1996
Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal systemS Arver, A S Dobs, A W Meikle, et al.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Androgen replacement in the treatment of Klinefelter's syndrome: efficacy and safety of a nonscrotal permeation-enhanced testosterone transdermal systemA W Meikle, A S Dobs, S Arver, et al.The Prostate|May 1, 1994
Effect of 5-alpha-reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC-3R M Tuttle, S Loop, R E Jones, et al.Metabolism: Clinical and Experimental|September 14, 1999
Transforming growth factor beta-1 and beta-2 and type II receptor functional regulation of ALVA-101 human prostate cancer cellsA W Meikle, R E Swope, D Y Yin, et al.The Journal of Clinical Endocrinology and Metabolism|March 17, 2000
Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twinsA Bansal, D K Murray, J T Wu, et al.Genetic Epidemiology|January 1, 1988
Lifestyle and blood pressure levels in male twins in UtahM L Slattery, D T Bishop, T K French, et al.Journal of Clinical Pharmacology|May 23, 1998
Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal menD E Wilson, A W Meikle, S C Boike, et al.Clinical Endocrinology|March 14, 1998
Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal menS Arver, A S Dobs, A W Meikle, et al.Pageof 8